SEC Comment Letter 0000000000-24-011574 to Y-mAbs Therapeutics, Inc. (YMAB) (CIK 0001722964)
Y-mAbs Therapeutics, Inc. (YMAB) (CIK 0001722964)
Date: Oct. 15, 2024 · CIK: 0001722964 · Accession: 0000000000-24-011574
AI Filing Summary & Sentiment
File numbers found in text: 001-38650
Letter
October 15, 2024 Peter Pfreundschuh Chief Financial Officer Y-mAbs Therapeutics, Inc. 230 Park Avenue Suite 3350 New York, NY 10169 Re:Y-mAbs Therapeutics, Inc. Form 10-K for Fiscal Year Ended December 31, 2023 File No. 001-38650 Dear Peter Pfreundschuh: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
October 15, 2024
Peter Pfreundschuh
Chief Financial Officer
Y-mAbs Therapeutics, Inc.
230 Park Avenue
Suite 3350
New York, NY 10169
Re:Y-mAbs Therapeutics, Inc.
Form 10-K for Fiscal Year Ended December 31, 2023
File No. 001-38650
Dear Peter Pfreundschuh:
We have completed our review of your filings. We remind you that the company and
its management are responsible for the accuracy and adequacy of their disclosures,
notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences